"Pyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
| Descriptor ID |
D011725
|
| MeSH Number(s) |
D03.383.725
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyridines".
Below are MeSH descriptors whose meaning is more specific than "Pyridines".
This graph shows the total number of publications written about "Pyridines" by people in this website by year, and whether "Pyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 3 | 5 |
| 1999 | 3 | 2 | 5 |
| 2000 | 0 | 4 | 4 |
| 2001 | 5 | 7 | 12 |
| 2002 | 1 | 4 | 5 |
| 2003 | 6 | 5 | 11 |
| 2004 | 3 | 8 | 11 |
| 2005 | 7 | 11 | 18 |
| 2006 | 9 | 8 | 17 |
| 2007 | 16 | 5 | 21 |
| 2008 | 21 | 10 | 31 |
| 2009 | 18 | 11 | 29 |
| 2010 | 12 | 9 | 21 |
| 2011 | 21 | 23 | 44 |
| 2012 | 17 | 10 | 27 |
| 2013 | 14 | 10 | 24 |
| 2014 | 14 | 18 | 32 |
| 2015 | 21 | 11 | 32 |
| 2016 | 16 | 17 | 33 |
| 2017 | 12 | 14 | 26 |
| 2018 | 22 | 12 | 34 |
| 2019 | 14 | 13 | 27 |
| 2020 | 20 | 12 | 32 |
| 2021 | 30 | 21 | 51 |
| 2022 | 2 | 22 | 24 |
| 2023 | 2 | 7 | 9 |
| 2024 | 8 | 2 | 10 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyridines" by people in Profiles.
-
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study. Lancet Oncol. 2024 Apr; 25(4):474-487.
-
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial. Nat Commun. 2024 Mar 19; 15(1):2446.
-
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer. 2024 Apr; 190:107512.
-
Potentiating the radiation-induced type I interferon antitumoral immune response by ATM inhibition in pancreatic cancer. JCI Insight. 2024 Feb 20; 9(6).
-
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024 Feb 14; 16(734):eadj5962.
-
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024 Apr; 9(4):310-322.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.
-
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study. Thyroid. 2024 01; 34(1):26-40.